HER2 Positive Breast Cancer Clinical Trial
Official title:
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer : a Single-arm,Ahead , Open-label Study
Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors.This study is a single-arm, prospective, open label clinical study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel given as neoadjuvant treatment in HER2 positive early stage or locally advanced breast cancer.
Neoadjuvant therapy is the standard treatment for locally advanced breast cancer and is used to reduce tumors to make them operable, and to increase breast-conserving rates. In recent years, the anti-HER2 treatment mode, which is double-blocked by a combination of dual-targeted drugs, has obtained clinical approval in adjuvant therapy and neoadjuvant therapy. Pyrotinib is an oral tyrosine kinase inhibitor targeting both HER-1 and HER-2 receptors. Based on previous clinical studies, we designed the study to explore the possibility of Pyrotinib in combination with Trastuzumab plus Docetaxel given as neoadjuvant treatment in HER2 positive early stage or locally advanced breast cancer. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01904903 -
Cardiac Safety Study in Patients With HER2 + Breast Cancer
|
Phase 2 | |
| Completed |
NCT02476539 -
Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT01840306 -
Exosomal and Free Extracellular RNAs and Proteins as Predictive Biomarkers for HER2 Therapies in Breast Cancer
|
||
| Recruiting |
NCT01785420 -
Pre Operative Trastuzumab in Operable Breast Cancer
|
Phase 3 | |
| Recruiting |
NCT05132582 -
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
|
Phase 3 | |
| Terminated |
NCT00817362 -
Efficacy and Safety of IPI-504 With Trastuzumab Pretreated, Locally Advanced or Metastatic HER2 Positive Breast Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT03947242 -
Neoadjuvant Study of Pyrotinib and Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Breast Cancer.
|
N/A | |
| Terminated |
NCT02213744 -
MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in HER2-Positive Locally Advanced/Metastatic Breast Cancer Patients
|
Phase 2/Phase 3 | |
| Completed |
NCT02362958 -
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
|
Phase 2 | |
| Completed |
NCT02614794 -
A Study of Tucatinib vs. Placebo in Combination With Capecitabine & Trastuzumab in Patients With Advanced HER2+ Breast Cancer
|
Phase 2 | |
| Completed |
NCT03013504 -
A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin® in HER2+ Early Breast Cancer Patients
|
Phase 3 | |
| Completed |
NCT02682693 -
Denosumab as an add-on Neoadjuvant Treatment (GeparX)
|
Phase 2 | |
| Completed |
NCT02125344 -
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
|
Phase 3 | |
| Active, not recruiting |
NCT04539938 -
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT05252988 -
Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib
|
Phase 2 | |
| Terminated |
NCT02963363 -
Adapted Physical Activity for Breast Cancer HER2 Positive Patient
|
N/A | |
| Completed |
NCT02705859 -
Phase Ib/II Trial of coPANlisib in Combination With Trastuzumab in HER2-positive Breast Cancer. (Panther Study)
|
Phase 1 | |
| Active, not recruiting |
NCT02993198 -
A Prospective Study of Breast Cancer Patients With Abnormal Strain Imaging
|
Phase 2 |